Candida rapid test could reduce mortality rates, study says

04/26/2013 | Medscape (free registration)

The T2Candida rapid blood test created by T2 Biosystems may significantly reduce mortality rates for patients diagnosed with Candida infection, which is the fourth-highest cause of hospital-acquired infections, researchers reported in Science Translational Medicine. Study investigator Dr. Eleftherios Mylonakis of Brown University said time to diagnosis is an important factor in Candida-related mortality and each hour of delay increases the risk.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC